Performance of rapid diagnostic tests for detection of Hepatitis B and C markers in HIV infected patients

Barbosa, Jakeline Ribeiro; Colares, Jeová Keny Baima; Flores, Geane Lopes; Cortes, Vanessa Faria; Miguel, Juliana Custódio; Portilho, Moyra Machado; Marques, Vanessa Alves; Potsch, Denise Vigo; Brandão‐Mello, Carlos Eduardo; Amendola-Pires, Marcia; Pilotto, José Henrique; Lima, Danielle Malta; Lampe, Elisabeth; Villar, Lívia Melo

doi:10.1016/j.jviromet.2017.08.001

Cited by 15 publications

(12 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other recent studies have reported sensitivities for HBsAg rapid test of 92.3% to 100% 7,36‐41 ; these studies were conducted in laboratory settings using only serum or plasma samples 36,37,40,41 and/or had a limited number of HBsAg‐positive subjects (n ≤ 14) 7,38,39 . A sensitivity of 95.2% in fingerstick or venous whole blood samples for an HBsAg test (All Test Biotech Hangzhou China) used at the point of care was reported in a Malaysian study including 295 subjects, of whom 145 were HBsAg‐positive 42 .…”

Section: Discussionmentioning

confidence: 99%

Clinical performance of Determine HBsAg 2 rapid test for Hepatitis B detection

Avellón

Ala

Díaz

et al. 2020

Journal of Medical Virology

View full text Add to dashboard Cite

Hepatitis B virus (HBV) infection is estimated to affect 292 million people worldwide, 90% of them are unaware of their HBV status. The Determine HBsAg 2 (Alere Medical Co, Ltd Chiba Japan [Now Abbott]) is a rapid test that meets European Union (EU) regulatory requirements for Hepatitis B surface antigen 2 (HBsAg) analytical sensitivity, detecting the 0.1 IU/mL World Health Organization (WHO) International HBsAg Standard. This prospective, multicentre study was conducted to establish its clinical performance. 351 evaluable subjects were enrolled, 145 HBsAg‐positive. The fingerstick whole blood sensitivity and specificity were 97.2% and 98.5% (15′ reading, reference assay cut‐off 0.05 IU/mL), sensitivity increasing to 97.9% with the prespecified cut‐off 0.13 IU/mL (EU regulations). The venous whole blood, serum and plasma sensitivity was 97.2%, 97.9%, and 98.6%, respectively (15′ reading); reaching 99%, 99.5% and 100% specificity. A testing algorithm following up an initial positive fingerstick test result with plasma/serum test demonstrates 100% specificity. The Determine HBsAg 2 test gives 15‐minute results with high sensitivity and specificity, making it an ideal tool for point‐of‐care testing, with the potential to enable large‐scale population‐wide screening to reach the WHO HBV diagnostic targets. The evaluated test improves the existing methods as most of the reviewed rapid tests do not meet the EU regulatory requirements of sensitivity.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical performance of Determine HBsAg 2 rapid test for Hepatitis B detection

Avellón

Ala

Díaz

et al. 2020

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…However, it is emphasized that the use of immunochromatographic technology is recommended in screening and population studies, and it is necessary to interpret the results associated with the clinical and epidemiological peculiarities of each specific case. 38…”

Section: Discussionmentioning

confidence: 99%

Hepatitis B Immunization Analysis: Tracking of Antibody Levels among Dental Patients

Wakayama

et al. 2019

The Journal of Contemporary Dental Practice

View full text Add to dashboard Cite

Aim:To verify the immunization status of dental students against HBV using an immunochromatographic rapid test and explore its associated protective and preventive effects against the disease. Material and methods:This transversal epidemiological study was conducted in a public dental school in Brazil. A total of 263 dental students who were at clinical practice were invited to participate in the study. A semi-structured questionnaire that investigated the issues related to the theme was created for data collection. An immunochromatographic test for the detection of anti-Hepatitis B surface antigen was used to verify the immunization status. Data were analyzed using the Statistical Package for the Social Sciences (SPSS).Results: Approximately 59.2% of the participants did not know the etiological agent of hepatitis B infection, and 36.6% did not know the number of doses of hepatitis B vaccines. Furthermore, 53.2% of the participants were immunized against HBV. Logistic regression showed that those who received less than three doses of the vaccine (OR = 2.539) or did not know how many doses they received (OR = 3.022) had higher risks of not developing the immunity. Moreover, age (OR = 0.834) was a protective factor against non-immunization.Conclusion: There was a low prevalence of dental students who were immunized against HBV. The number of vaccine doses received and the participants' age had significant associations with the immunization status. Clinical significance:Deals with an issue of major impact on the public health because of the high rates of hepatitis B in the general population, as well as the lack of knowledge of the subject by a large part of dental surgeons and dental students.

show abstract

“…Since HIV and HBV present similar modes of transmission, coinfection has been reported . In this context, it is important to identify those HIV‐infected individuals who are susceptible to HBV infection through detecting anti‐HBs and to recommend HBV vaccination to those who do not present anti‐HBs.…”

Section: Introductionmentioning

confidence: 99%

“…[11][12][13][14][15] Since HIV and HBV present similar modes of transmission, coinfection has been reported. 16,17 In this context, it is important to identify those HIV-infected individuals who are susceptible to HBV infection through detecting anti-HBs and to recommend HBV vaccination to those who do not present anti-HBs. In low resource areas, it is very difficult to collect, transport, and test serum samples, making DBS assays a powerful tool in increasing access to diagnostic testing.…”

mentioning

confidence: 99%

Assessing hepatitis B immunity using dried blood spot samples from HIV+ individuals

Flores

Cruz

Miguel

et al. 2018

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

This study aims to evaluate the utility of an optimized enzyme immunoassay (EIA) to detect and quantify antibodies against hepatitis B surface antibody (anti-HBs) in dried blood spots (DBSs) within the context of human immunodeﬁciency virus (HIV) status. Serum and DBS samples were obtained from 56 HIV+ and 99 HIV- patients and subjected to EIA for the detection of anti-HBs, where sample volume and cut off value were modified for DBS testing. Sensitivities of anti-HBs detection in DBS were 79.8% and 76.8% in HIV- and HIV+ subjects, respectively. Concordant results for anti-HBs in serum and DBS presented high mean CD8 cell counts, HIV viral load and optical density (OD) values of anti-HBs. Anti-HBs titers were significantly higher in serum, whether or not anti-HBs titers were detected in DBS. It was possible to detect anti-HBs in DBS as low as 17.4 and 27.3 IU/mL among HIV+ and HIV- subjects, respectively. In conclusion, DBS can be used to detect and quantify anti-HBs in HIV-infected individuals, which could increase access to diagnosis and vaccination.

show abstract

Performance of rapid diagnostic tests for detection of Hepatitis B and C markers in HIV infected patients

Cited by 15 publications

References 20 publications

Clinical performance of Determine HBsAg 2 rapid test for Hepatitis B detection

Clinical performance of Determine HBsAg 2 rapid test for Hepatitis B detection

Hepatitis B Immunization Analysis: Tracking of Antibody Levels among Dental Patients

Assessing hepatitis B immunity using dried blood spot samples from HIV+ individuals

Contact Info

Product

Resources

About